SCHEMBL2962175

SCHEMBL2962175

CC(OC(=O)/C=C/C(=O)OC(C)(c1ccccc1)c1ccccc1)(c1ccccc1)c1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 1/20 0.48
HIF1A Q16665 1/20 0.48
MAPT P10636 3/20 0.45
KMT2A Q03164 2/20 0.45
KCNN4 O15554 1/20 0.44
ALDH1A1 P00352 4/20 0.43
ALOX15 P16050 1/20 0.43
HDAC3 O15379 1/20 0.42
HDAC4 P56524 1/20 0.42
HDAC1 Q13547 1/20 0.42
HDAC7 Q8WUI4 1/20 0.42
HDAC2 Q92769 1/20 0.42
HDAC10 Q969S8 1/20 0.42
HDAC11 Q96DB2 1/20 0.42
HDAC8 Q9BY41 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
HDAC9 Q9UKV0 1/20 0.42
HDAC5 Q9UQL6 1/20 0.42
MAPK1 P28482 1/20 0.41
CYP1A2 P05177 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2962178 0.94 HCAR2 (0.49) CYP2C19HIF1AMAPTKMT2AKCNN4
SCHEMBL28803460 0.94 HCAR2 (0.49) CYP2C19HIF1AMAPTKMT2AKCNN4
SCHEMBL2962181 0.94 HCAR2 (0.49) CYP2C19HIF1AMAPTKMT2AKCNN4
SCHEMBL3169549 0.84 CYP2C19 (0.46) CYP2C19HIF1AMAPTKMT2AKCNN4
SCHEMBL7087313 0.81 HCAR2 (0.47) CYP2C19HIF1AMAPTKMT2AKCNN4
SCHEMBL7086342 0.81 HCAR2 (0.47) CYP2C19HIF1AMAPTKMT2AKCNN4
SCHEMBL7086340 0.81 HCAR2 (0.47) CYP2C19HIF1AMAPTKMT2AKCNN4
SCHEMBL11244960 0.80 CYP2C19 (0.54) CYP2C19HIF1AMAPTKMT2AKCNN4
SCHEMBL11244956 0.80 CYP2C19 (0.54) CYP2C19HIF1AMAPTKMT2AKCNN4
SCHEMBL11385768 0.80 CYP2C19 (0.54) CYP2C19HIF1AMAPTKMT2AKCNN4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7763263-B2 Skin external agents and drugs KAO CORPORATION (JP) 2010-07-27 US disclosed
EP-1249237-B1 Topical cosmetic and pharmaceutical composition comprising specific alkoxylated diester of fumaric acid KAO CORP (JP) 2007-07-18 EP disclosed
US-20060177408-A1 Skin external agents and drugs KANEBO COSTMETICS INC. 2006-08-10 US disclosed
US-7037489-B2 Skin external agents and drugs KANEBO COSMETICS, INC. (JP) 2006-05-02 US disclosed
US-20030185786-A1 Skin external agents and drugs KAO CORPORATION (JP) 2003-10-02 US disclosed
EP-1249237-A1 SKIN EXTERNAL AGENTS AND DRUGS Kanebo Limited (JP) 2002-10-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060177408-A1 Skin external agents and drugs CUTA, F12, NFE2 CYP2C19 1009/4885HIF1A 597/4885MAPT 2612/4885
US-20030185786-A1 Skin external agents and drugs AREG, RARG, FRG1 CYP2C19 2625/4885HIF1A 186/4885MAPT 3966/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.